Massachusetts pain-management treatment agreements, documented from statute outward

Status: Massachusetts evidence build reviewed through October 4, 2026. This library separates the narrow statewide statutory mandate, professional hydrocodone-only rules, prescription-monitoring duties, workers’ compensation guidance, tapering safeguards, pain-management insurance reform, and the formal change path.

Use this Massachusetts record

What is required M.G.L. c.94C §18A requires a written pain-management treatment agreement when a practitioner recommends an extended-release or long-acting opioid during long-term pain management.
Who it applies to Patients and practitioners in that narrower statutory ER/LA opioid pathway; workers’ compensation and profession-specific hydrocodone rules are separate layers.
Who can change it The Massachusetts Legislature controls §18A; professional boards and agencies control narrower implementing rules and guidance.
What to do next See the change path or submit a Massachusetts agreement.

Current statutory baseline

M.G.L. c.94C §18A requires a written pain-management treatment agreement when a practitioner recommends an extended-release or long-acting opioid during the course of long-term pain management. The agreement must address benefits and risks of abuse or misuse and be placed in the patient’s medical or electronic health record.

Layer Massachusetts rule
Statewide statute Agreement required for covered long-term use of extended-release or long-acting opioids.
Hydrocodone-only professional rules Additional agreement duties for certain non-abuse-deterrent extended-release hydrocodone products.
MassPAT Separate monitoring requirement for Schedule II/III narcotics and benzodiazepines.
Workers’ compensation guideline Broadly recommends written informed agreements for all long-term opioid patients in that system.

Massachusetts state-level records

Important scope correction

Massachusetts is not accurately described as requiring every patient on long-term opioids to sign a pain contract. The statutory mandate in §18A is tied to extended-release or long-acting opioids in long-term pain management. Broader agreement expectations found in workers’ compensation guidelines, payer policies, or individual clinics are separate layers.

Professional rules add a narrower medication-specific layer

Massachusetts physicians, dentists, APRNs and historically physician assistants have parallel rules for hydrocodone-only extended-release medication that is not abuse-deterrent. Those rules require risk assessment, monitoring review, risk/benefit discussion, a Pain Management Treatment Agreement, and related documentation.

MassPAT remains separate

Massachusetts requires MassPAT review each time a Schedule II or III narcotic or benzodiazepine prescription is issued, subject to exceptions. A signed agreement does not replace that duty.

Massachusetts-published tapering guidance questions contract use

Massachusetts hosts 2023 provider guidance noting limited evidence that opioid contracts improve health or reduce misuse, warning that patients may feel coerced or stigmatized, suggesting non-signed treatment-plan documents as an alternative, and stating that abandonment should not follow agreement violation. The hosting agency expressly states that this guidance is not official DIA/HCSB policy.

Workers’ compensation is broader but not a universal mandate

The Department of Industrial Accidents’ October 2024 Chronic Pain Treatment Guideline recommends written informed agreements for all long-term opioid patients and outlines testing, refill, tapering, and termination subjects. The Department also states that its guidelines are not mandates and that deviation may be appropriate.

2025 pain-management access reform

For covered insured plans beginning July 1, 2025, Massachusetts expanded access requirements for non-medication, nonsurgical, and non-opioid pain treatment and restricted prior authorization or more burdensome utilization controls for certain alternatives. The reform does not repeal §18A.

Legislative origin

Chapter 52 of the Acts of 2016 created §18A. Massachusetts professional boards had already adopted narrower hydrocodone-only extended-release rules in 2014.

Formal change route

Because the core agreement mandate is statutory, repeal or narrowing requires amendment by the Massachusetts General Court. The current Joint Committee on Public Health chairs are Sen. William J. Driscoll, Jr. and Rep. Marjorie C. Decker. DPH Commissioner Robbie H. Goldstein, MD, PhD oversees important implementation functions, but DPH cannot repeal §18A administratively.

Submit a missing Massachusetts agreement

Submit a Massachusetts Contract for Care

Primary Massachusetts authorities

Reviewed: October 4, 2026.

Evidence boundary: Massachusetts has multiple overlapping contract and monitoring frameworks. The statewide statutory mandate, professional rules, workers’ compensation guidance, payer policies, and clinic-created terms must not be collapsed into one universal requirement.